<DOC>
	<DOCNO>NCT00100243</DOCNO>
	<brief_summary>This Phase 2 , open-label study subject androgen-independent prostate cancer progress follow treatment LHRH agonist . Up 22 subject enrol . Enrollment monitor ensure subject enrol base rise prostate specific antigen ( PSA ) criterion . Subjects treat abarelix ( Plenaxis ) 100 mg intramuscularly ( IM ) every 2 week 12 week ( total dose 600 mg ) .</brief_summary>
	<brief_title>Study Abarelix Androgen-Independent Prostate Cancer Progressing After Agonist Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Abarelix</mesh_term>
	<criteria>Signed informed consent Histologically cytologically confirm prostate cancer progress within 60 day start screen despite castrate level testosterone treatment LHRH agonist . Progression define one following : *A rise PSA , define least two consecutive rise PSA reference value ( PSA # 1 ) . The first rise PSA ( PSA # 2 ) must take least one week PSA # 1 . A third PSA ( PSA # 3 ) require great PSA # 2 ; , fourth PSA ( PSA # 4 ) require great PSA # 2 , OR The appearance new metastatic lesion bone scan , OR Progression know lesion appearance new metastatic lesion CT , MRI , chest xray , radiographic evaluation . Subject whose hormonal therapy include antiandrogen must antiandrogen discontinue prior start screening ( least 6 week bicalutamide least 4 week otherwise ) . If reduction PSA antiandrogen withdrawal , subject must continue demonstrate progression define anti androgen withdrawal eligible . ECOG Performance Status ≤ 3 Age ≥ 18 year age Life expectancy ≥ 6 month Serum testosterone less equal 50 ng/dL PSA ≥ 5 ng/mL ( progression determine rise PSA ) WBC great equal 3,000/mm3 Hematocrit ≥ 30 % Platelet count great equal 100,000/mm3 Serum creatinine less equal 2 x upper limit normal ( ULN ) Bilirubin ( direct total ) less equal 2 x ULN SGPT ( ALT ) SGOT ( AST ) less equal 2 x ULN A subject ineligible participate study meet follow criterion : Prior treatment prostate cancer : Chemotherapy Radiopharmaceutical strontium samarium Diethylstilbesterol another estrogen agonist antagonist Ketoconazole Aminoglutethimide Current treatment Class IA ( e.g. , quinidine , procainamide ) Class III ( e.g. , amiodarone , sotalol ) antiarrhythmic medication Currently take PC SPES History allergy LHRH agonist GnRH antagonist Major surgery within 4 week Serious medical illness , include malnutrition , judgment investigator would preclude protocol treatment Significant cardiovascular illness define NYHA class III IV congestive heart failure unstable angina within 6 month , myocardial infarction within 12 month , deep venous thrombosis within 2 year , history acute pulmonary embolism Active second malignancy nonmelanoma skin cancer superficial bladder cancer Any uncontrolled infection , include HIV Any experimental therapy within 4 week prior study entry QTc &gt; 450 msec screen ECG obtain investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>androgen-independent</keyword>
	<keyword>prostate cancer</keyword>
</DOC>